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Key points 
• A synthesis method was developed comparing the roles of 431 mouse genes in 
arterial thrombosis with or without affecting hemostasis. 
• A network of protein interactions in thrombosis/hemostasis revealed high 
similarity in mouse and man, and identified candidate proteins.   
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Abstract 
Antithrombotic therapies reduce cardiovascular diseases by preventing arterial 
thrombosis and thromboembolism, but at expense of increased bleeding risks. Arterial 
thrombosis studies using genetically modified mice have been invaluable for 
identification of new molecular targets. Because of low sample sizes and heterogeneity 
in approaches or methodologies, a formal meta-analysis to compare studies of mice 
with single gene defects encountered major limitations. To overcome these, we 
developed a novel synthesis approach to quantitatively scale 1514 published studies of 
arterial thrombus formation (in vivo and in vitro), thromboembolism and tail bleeding of 
genetically modified mice. Using a newly defined consistency parameter (CP), indicating 
the strength of published data, comparisons were made of 431 mouse genes, of which 
17 consistently contributed to thrombus formation without affecting hemostasis. Ranking 
analysis indicated high correlations between collagen-dependent thrombosis models in 
vivo (FeCl3 injury or ligation/compression) and in vitro. Integration of scores and CP 
values resulted in a network of protein interactions in thrombosis and hemostasis 
(PITH), which was combined with databases of genetically linked human bleeding and 
thrombotic disorders. The network contained 2,946 nodes linked to modifying genes of 
thrombus formation, mostly with expression in megakaryocytes. Reactome pathway 
analysis and network characteristics revealed multiple novel genes with potential 
contribution to thrombosis/hemostasis. Studies with additional knockout mice revealed 
that 4/8 (Apoe, Fpr2, Ifnar1, Vps13a) new genes were modifying in thrombus formation. 
The PITH network further: (i) revealed a high similarity of murine and human hemostatic 
and thrombotic processes, and (ii) identified multiple new candidate proteins regulating 
these processes. 
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Introduction 
Cardiovascular disease, due to vaso-occlusive arterial thrombosis or thromboembolism, 
is a leading cause of disability and death worldwide.1 Extensive research over the last 
decades has provided drugs that result in a significant, albeit incomplete reduction of 
disease-related mortality and morbidity. Apart from pharmacological agents lowering 
plasma lipids and blood pressure, antiplatelet and anticoagulant agents are effective in 
the secondary prevention of thrombotic complications.2-4 Yet, current treatment 
regimens are still partly effective, while causing bleeding complications in at least 2% of 
the patients. This has led to a continued search for better targeted antithrombotic 
medication with minimal bleeding. 
In the past two decades, hundreds of mouse studies have been performed to 
evaluate consequences of genetic modification or pharmacological intervention in 
experimental models of arterial thrombosis or thrombo-embolism.3, 5, 6 The connecting 
aim of such studies is to disclose particular platelet, coagulation or vascular proteins 
that regulate thrombosis and/or hemostasis. However, these studies typically use low 
numbers of mice (typically 6-12), and assess arterial thrombus formation or thrombo-
embolism in vivo or in vitro, using different methodologies and measurement outcomes. 
This variation has hampered a systematic comparison of the use of thrombosis models 
across genes. The few published reviews provide qualitative rather than quantitative 
descriptions of the effects of genetic modification on thrombus formation or tail 
bleeding.3, 5, 7, 8 On the other hand, many of the published effects of murine gene 
deletion faithfully phenocopy the known effects of Mendelian inherited bleeding and 
platelet disorders in man, thus proving their relevance for disease.9, 10 This prompted us 
to develop new means for quantitative comparison of published studies regarding 
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altered thrombosis and bleeding tendencies as a consequence of genetic modification 
in mice. 
Published reports on murine arterial thrombosis have in common an 
experimental approach, in which vascular damage is induced by activation or injury of 
the endothelium to cause exposure of the collagen-containing subendothelial matrix.10 
Nevertheless, in vivo methods differ regarding (i) the type of injured vascular bed, (ii) 
the type and strength of the injury, (iii) equipment and detection methods, and (iv) 
outcome parameters. Hence, for systematic comparison of multiple studies, an 
analytical tool needs to be developed that is scaled and takes into account these 
variables. The same applies to in vitro tests, where microfluidics devices for whole blood 
perfusion are employed as proxy measurements of arterial thrombus formation.11-13 
Such in vitro tests are relevant from a translational point of view, since the same 
devices can be used to detect deficiencies in human platelet and coagulation activity 
and to determine the efficacy of antithrombotic medication.13-17 
In the present paper, we developed and validated a scaling procedure as a 
synthesis approach to compare published studies on effects of genetic modification on 
arterial thrombus formation, thromboembolism and/or tail bleeding. This synthesis gave 
an unprecedented insight into the relative roles of multiple mouse genes, in majority 
regulating platelet, coagulation or vascular functions. 
 
Methods 
For a more extended description of the methods, see supplementary file. 
 A PubMed search over the years 1980-2018 was performed to identify papers on 
mouse studies in relation to arterial thrombus formation, thromboembolism and tail 
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bleeding (Suppl. Table 1). From these papers information on genetics, experimental 
models and outcome parameters was gathered (Data File 1). 
 As an alternative synthesis approach, 1514 studies* were grouped per 
experimental method, vascular bed of injury, and outcome thrombus parameter (mass-
dependent, time-dependent and stability measurements, bleeding times) and then 
normalized on a 3-point or 5-point scale. Mean scores per group, parameter type and 
gene were compared using the non-parametric Kendall's Tau-c test. To assess 
consistency and strength of scaled studies per gene, a consistency parameter (CP) was 
defined as 1 - log (P), with P values from a one-sample t-test. 
 Animals came from breeding programs of the Wellcome Sanger Institute Mouse 
Genetics Programme (Cambridge, United Kingdom) and the Institute for Cardiovascular 
Prevention in Munich (Germany). Animal experiments were approved by the local 
Animal Experimental Committees. 
 
Results 
 
Data collection of mouse studies reporting on genetic modification or 
pharmacological intervention affecting arterial thrombosis, thromboembolism or 
tail bleeding 
A PubMed search was performed across scientific publications over the period 1980-
2018, resulting in 610 publications containing quantified data (with statistics) on effects 
of genetic or pharmacological perturbation on arterial thrombus formation, 
thromboembolism or tail bleeding in mice. The majority of the papers concerned mice 
                                                      
*
1431 studies published before January 2018 
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with a single genetic deficiency, resulting in altered platelet, coagulant or vascular 
function. The published studies were classified (Figure 1) as in vivo arterial thrombosis 
(class I), in vivo thromboembolism (class II), in vitro arterial thrombus formation (class 
III), or tail bleeding (class IV). Manuscripts as well as published reviews were screened 
for further primary sources, thereby, including another 32 publications. Individual studies 
were defined as reporting on effects of genetic modification per vascular bed or way of 
injury, resulting in a database of 1514 studies* (Data File 1). 
 
Conventional meta-analysis and limitations 
As a first approach to quantitatively compare outcomes of thrombosis studies per 
mouse gene, a conventional meta-analysis was performed for the most studied mouse 
strains. Given the diversity between studies (thrombosis model, detection method, and 
parameter measured), a standard random effects model was considered most 
appropriate. To achieve a certain degree of inter-study consistency, only studies were 
included where FeCl3 was used to induce thrombosis in either the carotid, mesenteric or 
femoral arteries/arterioles, and where time-dependent parameters were reported (see 
Suppl. Methods). For six genes, data could thus be obtained from a small number (n) of 
studies: Cd36 (4), Clec1b (3), F12 (4), Fcer1g (2), Gp6 (6) and Vwf (3) (Figure 2). Meta-
analysis per gene, using the Cochrane group RevMan 5.1 program, pointed to a 
significantly prolonged thrombus formation in mice with genetic deficiency in F12, Gp6 
or Vwf (P=0.0008-0.003), while there was a tendency to prolongation in mice lacking 
Cd36, Clec1b or Fcer1g (P=0.05-0.08). A limitation of this meta-analysis approach 
however is the large heterogeneity index for all genes (I2=73-88%), even when 
statistical significance is reached. We reasoned that this high heterogeneity is 
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unavoidable, since animal experiments are de facto quite small in size, and furthermore 
vary in experimental conditions and outcome parameters. We further noticed that a 
heterogeneity test is low in power, when sample size is small and few trials are 
included.18 This prompted us to search for a better method to compare and normalize 
effects of genetic knock-out in a larger set of published studies. 
 
Study scaling and subdividing of parameters of arterial thrombus formation, 
thromboembolism and tail bleeding 
As an alternative approach to compare and normalize published effects of gene 
inactivation on arterial thrombus formation and bleeding, we searched for a synthesis 
procedure that is condition independent. A simple method is to scale the published 
effect of genetic perturbation (e.g. quantifiable difference between wild type and 
genetically modified mice) on a 3-point or 5-point scale (Figure 1). Herein, the 3-point 
scale discriminates between a decrease and increase of the parameter determining the 
thrombotic process; while the 5-point scale further distinguishes between a 
moderate/strong decrease and increase. For convenience, we refer to the results of this 
scaling as 'scores.' 
For the database of 1431 studies (i.e., those published before January 2018) we 
performed a consistency analysis to determine if scores per class were comparable 
depending on the type of vascular bed, the injury trigger, and the parameter of 
measurement. The original papers were mined for quantitative data on arterial 
thrombosis, thromboembolism or tail bleeding (Suppl. methods). Weighing was not 
performed, because of the similar sample size of studies and the lack of calibration 
options. 
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For studies on thrombus formation in vivo (class I) and in vitro (class III), we 
separated the published data into time-, mass- or stability-dependent parameters. To 
accommodate different measurement outcomes, we further divided the mass-
dependent parameters in three sub-parameters, i.e. platelet adhesion, vessel occlusion 
and thrombus size (Suppl. Table 2). 
Comparative analysis within studies of class I and class III, applied to the whole 
database, showed significant correlations between the three mass-dependent sub-
parameters (class I: bi-biii, class III: gi-giii), at 3-point and mostly also at 5-point scale, 
with Kendall's τ ≥ 0.54 (P<0.050) (Suppl. Table 3A-B). This allowed combination of the 
sub-scores into one mass-dependent score per study. Subsequently, correlation 
analysis pointed to a high similarity of time-, mass- and stability-dependent parameters, 
again within individual studies of the whole database (Suppl. Table 3C-D). In class I, 
these parameters correlated with P<0.001, except when comparing time and stability 
parameters at a 5-point scale (P=0.226). In class III, with lower sample size, the time- 
and mass-dependent parameters correlated with P=0.046 (3-point) or 0.072 (5-point); 
thrombus stability was hardly measured in class III. Together, the overall high 
consistency of scaling of time-, mass- and stability-dependent parameters made it 
possible to combine these per study into one mean synthesis score (3- and 5-point 
scale), as a calibrated outcome of the gene modifying effect in that particular vascular 
bed and injury type. Studies of arterial thromboembolism (class II) and tail bleeding 
times (class IV) were also scaled at 3- and 5-point. 
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Comparison of scaling for different experimental models of thrombus formation 
and thromboembolism 
In 205 cases, mice of the same breeding were used in one paper for class I/II in vivo 
studies as well as for class III in vitro studies (Data File 1, same rows). This allowed us 
to directly compare the scores of such studies (Suppl. Table 4). For the database as a 
whole, this resulted in significant correlations for the 3- and 5-point scaling of class I 
(P<0.001, n=151) and class II (P=0.006 and 0.268, n=14) studies, when compared to 
class III studies in the same paper. Hence, overall, the scaling of the in vitro thrombus 
formation appears to be in good agreement with that of in vivo arterial thrombosis. 
Next, we compared per gene the results obtained for different vascular beds or 
injury types. Grouping the studies according to these variables (Figure 1 and Suppl. 
Table 2) revealed that, for class I studies, the mostly used vascular beds were carotid 
artery > mesentery > cremaster > aorta; while the most popular injury methods were 
FeCl3 > laser > photochemical > vessel ligation or compression > electrolytic injury 
(Suppl. Figure 1A). For class II, the majority of papers applied injection of 
collagen/epinephrine, with fewer studies using tissue factor or reporting unprovoked 
thrombosis (Suppl. Figure 1B). Concerning class III, mostly collagen type-I was used as 
thrombogenic surface (Suppl. Figure 1C). Class IV bleeding time studies were not sub-
divided. 
For comparison of the different experimental approaches in the studies, groups in 
class I were combined with respect to vascular bed or injury mode. Regression analysis 
indicated significant correlations at 3-point and 5-point scales between the scores for 
carotis, mesentery and cremaster injury, when averaged per gene (Table 1). 
Furthermore, we found highly significant (P<0.001) correlations of mean scores per 
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gene in class I for carotid or mesenteric injury (i.e., collagen-dependent thrombosis 
models) with class III study scores (i.e., collagen-induced thrombus formation in vitro). 
Markedly, the scaling of class I studies using cremaster injury (laser-induced, 
considered to be less collagen-dependent) again correlated with that of class III studies 
(P<0.001, 3- and 5-point). 
When comparing different injury modes in class I, the scaling per gene for FeCl3 
studies correlated significantly (P≤0.005, 3- and 5-point) with that for laser, 
photochemical or ligation/compression injuries (Table 1). Furthermore, class III scores 
of collagen-dependent thrombus formation were related on 3-point scale (P=0.006, low 
n=14) but not on 5-point scale (P=0.286) with class II scores (thromboembolism with 
frequent collagen/epinephrine injection). Taken together, this analysis revealed that, 
overall, the scaling for classes I, II and III gave similar outcomes for effects of a certain 
gene deficiency, irrespective of the arterial vascular bed, injury mode, injection of 
collagen or in vitro testing. 
 
Synthesis approach of scaled studies to compare roles of mouse genes in 
thrombus formation, thromboembolism and hemostasis 
Considering that the 5-point scale (classes I-III) is more discriminative than the 3-point 
scale, we used the former for comparative analyses of the 1431 studies. As a first 
approach, mean scaled scores were calculated per class and gene. For 409 genes, this 
resulted in information on 277, 79 and 161 genes for classes I, II and III, respectively 
(Figure 3A). For bleeding times (class IV), information was collected for 314 genes 
(Figure 3A). First analysis across all genes revealed that a gene defect with a negative 
score for arterial thrombosis was more frequently (69%) accompanied with prolonged 
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bleeding than unchanged bleeding (Figure 3C). 
 Subsequently, for the 35 best-investigated genes (n≥6 studies across classes I-
III, 65% collagen-dependent models), we evaluated the distribution of study scores in 
more detail (Figure 4A). We considered these scores as discretized ordinal variables 
with defined ranking; hence these could be treated as interval variables. This allowed 
calculation of 95% confidence intervals and P values, while keeping the rounded-off 
mean scaling per gene (Figure 4B). 
A standard method to assess distribution profiles of interval variables does not 
exist. Based on P values obtained from normalized data (per gene, see Methods), we 
therefore defined a consistency parameter (CP) as 1 - log(P), reflecting the uniformity 
and strength of the pooled study scores. Accordingly, we considered that a mean non-
zero scaling with CP > 2.30 (corresponding to P<0.05) consistently points to an anti- or 
prothrombotic propensity. 
 Following this synthesis approach it appeared that, for the best studied genes, 14 
genes with mean -2 score gave a CP > 2.30 (in decreasing order: Gp6, Fcer1g, F12, 
Vwf, Itgb3, Rasgrp2, P2ry12, Pik3cb, F8, Pdia3 > Tln1, F2, F9 > Lcp2) (Figure 4C). 
Furthermore, 13 out of 17 genes with a mean -1 score had a CP > 2.30 (Ptprj, F11, 
P2ry1 > F2rl3 > Orai1, Stim1, Serpine1, Gp1bb, Pld1 > Klkb1, Itga2, Selp, Clec1b). 
Regarding the 'prothrombotic' gene with mean score +1, Adamts13 gave a CP > 2.30. 
Negative scores of the genes Cd36, Itgb1, Jak2 and Vtn did not reach significance 
(Figure 4C). 
The suitability of this synthesis approach prompted us to generate mean scores 
and CP values for all genes. In this way, it is possible to compare, across all genes, not 
only the overall effect size (5-point scale) but also the consistency of the reported data 
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of a gene defect, regarding both arterial thrombosis/thromboembolism (class I-III) and a 
bleeding tendency (class IV). Data File 3 provides an overview for all gene defects (or 
pharmacological intervention), regarding mean class scores, CP values, and a short 
description on altered platelet, coagulant or vascular function. 
For 60 genes with CP>2.30 (P<0.05) and an arbitrary cutoff of n≥3 studies, the 
results are summarized in Table 2, separating mice with an 'antithrombotic' phenotype 
(negative class I-III scores) and a normal or prolonged bleeding time. For 17 genes, 
mostly encoding platelet receptor or signaling proteins or plasma coagulation proteins, 
there appears to be consistent evidence for a role in arterial thrombosis but not 
hemostasis. For 42 genes, encoding proteins with similar functions, the scaled data 
points to contribution to both thrombosis and hemostasis. In one case (deficiency in 
Ceacam1/2), a prothrombotic phenotype is accompanied with prolonged bleeding, 
possibly due to vascular changes. 
When comparing the human orthologues of these 42 genes, it appears that 
mutations are often associated with bleeding events,19 especially for those 
corresponding to mouse genes with a -2 bleeding score (Table 2). These include F8, 
F9, VWF, FERMT3, GPIBA, GPIBB, ITGB3, P2RY1, P2RY12, RASGRP2, TLN1 and 
NBEAL2. Interestingly, for several other genes (e.g., GNA13, MAP3K3, KCNIP3), 
evidence in humans of a possible role in human hemostasis is still unknown. We note 
here that, given the low prevalence of inherited Mendelian bleeding disorders, very little 
is known of a protective role in thrombosis in this group of rare patients with hemostatic 
insufficiencies. The mouse data would predict such a role. 
Antagonists for several human orthologous proteins are already in use for patient 
treatment (thrombin inhibitors, F2; integrin αIIbβ3 antagonists, ITGB3; P2Y12 antagonists, 
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P2RY12); or are studied in clinical trials (inhibitors of: factor XI and XII, F11, F12; 
glycoprotein VI, GP6; glycoprotein Ib-VWF, GPIBA, VWF; phosphoinositide 3-kinase-β, 
PIK3CB). 
 
Reactome biological pathway analysis of (modifying) genes in arterial thrombosis 
and hemostasis 
To translate the scoring per mouse gene/protein to human pathophysiology, we first 
performed an over-representation analysis using the Reactome database. This 
knowledgebase of biological pathways is elaborated for megakaryocytes, platelets and 
the coagulation system.20 Pathway analysis for 405 scored genes/proteins indicated that 
a substantial part of the Reactome-registered hemostatic system was covered (148/ 806 
proteins) (Data File 5). Well-covered pathways included platelet activation, 
platelet/neutrophil degranulation, and fibrin clot formation. Several unexpected 
pathways were also detected, e.g. linked to cancer (see Supplementary file). Additional 
Reactome attribute analysis, taking into account the scores per gene/protein, revealed 
pathways where mean scores for (modifying) proteins in class I-III were less negative 
than those for proteins in class IV (Data File 5). This concerned pathways of 12/15-
eicosatetraenoic synthesis, matrix metalloproteinases and common fibrin clot formation, 
suggesting that these may play a more prominent role in hemostasis. Conversely, mean 
scores for proteins of Toll-like receptor pathways were more negative in class I-III than 
those for proteins in class IV, suggesting a more prominent role in thrombosis (Data File 
5). 
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Network of genes and proteins implicated in arterial thrombus formation 
To further exploit the dataset, a Cytoscape network was constructed with human protein 
orthologues of 267 genes with modifying effects on arterial thrombosis (class I-III). 
Using these as primary baits, a network was obtained retrieving 2,679 first order 
interactors (novel nodes) and 19,721 interactions (edges) (Figure 5A). The expanded 
network of protein interactions in thrombosis and hemostasis (PITH) was used for 
further exploration of new (patho)physiological pathways (Data File 6). 
 In order to relate to human diseases, the network was linked to several large-
scale human genetic studies. As nodes, we could trace 54 genes of in total 72 genes 
linked to rare human Mendelian disorders of platelet or coagulation function, obtained in 
the NIHR BioResource Bleeding, Thrombotic and Platelet Disorders cohort,21 and 21 
out of 68 genes from a genome wide association study (GWAS) of platelet count and 
volume22 (Figure 5B). The latter set encompassed 147 DNA variants in the network out 
of 647 variants obtained in a more recent GWAS of platelet quantitative traits (Data File 
6).23 Regarding arterial thrombosis, 11 genes were identified in 39 loci from a GWAS of 
stroke,24 and 40 genes in 64 loci from a GWAS of coronary artery disease25 (Figure 5C). 
Thus, although the network was constructed from only 267 core proteins/genes, it 
covered substantial gene sets identified in GWAS and related studies. 
Subsequently, we evaluated node connections and node centrality 
characteristics, such as proximity to other nodes (high for core nodes) and tendency to 
sub-clustering (low for core nodes) (Data File 6). mRNA expression levels in human 
megakaryocytes were determined for the network (Suppl. Figure 4 and 5A). For the 
novel nodes, it appeared that a substantial part of the corresponding genes were 
transcribed in megakaryocytes (Suppl. Figure 4A and 5B), and that most of these had 1-
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4 connections with one or more modifying proteins in the network (Suppl. Figure 4B). 
Subsequently, we isolated the top 50 most connected novel proteins (Figure 5D), 
revealing some known proteins (Cbl, Fyn, Lck) but also proteins of novel pathways 
(Anxa, Grm, Lpar, Nmur family members). 
 
Altered thrombus formation of mice deficient in newly identified genes 
Taking into account the node characteristics, the PITH network was subsequently used 
to identify novel mouse genes with a possible role in arterial thrombosis. From the list of 
novel nodes with edges to modifying genes, we screened two groups of knockout mice 
for in vitro arterial thrombus formation (class III), which had not been evaluated yet in 
this way. One group came from the extensive Mouse Genetics breeding program of the 
Wellcome Sanger Institute in Cambridge (United Kingdom). These mice carried a 
homozygous deficiency in Bnip2 (regulating cell death), Dlg4 (membrane-associated 
guanylate kinase clustering signaling proteins), Grm8 (Gi-coupled metabotropic 
glutamate receptor 8), Ifnar1 (interferon receptor signaling via the JAK/STAT pathway) 
or Vps13a (involved in protein cycling through the trans-Golgi network) (Figure 6A). 
Mice deficient in two out of four genes with high mRNA expression in reference 
megakaryocytes (Figure 6B), i.e. Ifnar1 and Vps13a but not Bnip2 and Dlg4, gave a 
significant reduction in arterial thrombus formation (score -2). These findings are 
corroborated by recent papers showing that interferon I (ligand of Ifnar1 transcript) 
regulates platelet count and function;26 and that gene defects in human VPS13A are 
associated with chorea-acanthocytosis, where patients carry platelets with impaired 
granule secretion.27 In accordance with low mRNA expression in reference 
megakaryocytes, Grm8 deficiency did not affect thrombus formation (score 0). 
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The second group was provided by breeding programs of the Institute for 
Cardiovascular Prevention in Munich (Germany). This included animals with a 
homozygous deficiency in Apoe (apolipoprotein E, controlling the catabolism of 
lipoprotein triglycerides; affecting thrombosis in vivo, but not yet evaluated in class III), 
Fpr2 (Gi protein-coupled formyl peptide receptor 2), or Anxa1 (annexin A1, FPR2 
ligand) (Figure 6C). These genes have been implicated in arteriosclerosis, and appear 
with multiple edges in the PITH network. Transcripts are expressed at medium to high 
levels in the liver,28 but only Anxa1 and Apoe transcripts are detectable at low levels in 
megakaryocytes. We found that deficiencies in Apoe and Fpr2, but not Anxa1, positively 
modified thrombus formation (Apoe-/-, score +1 and Fpr2-/- score +2) (Figure 6D). This 
implies that the prothrombotic role of FPR2 is independent of its proposed ligand ANX1. 
It appeared that 4 from the 8 novel genes with a predicted contribution to arterial 
thrombus formation, showed a phenotype in thrombus formation (Ifnar1, Vps13a, Apoe, 
Fpr2). 
 
Discussion 
Formal meta-analyses were performed to compare studies investigating consequences 
of genetic deficiency for experimental arterial thrombosis. The analyses were greatly 
impaired by high heterogeneity, as a consequence of small sample size (typically n=6-
12) and differences in experimental set-up. To overcome these limitations, we 
developed an alternative synthesis approach, in which mouse studies of arterial 
thrombosis, thromboembolism, in vitro thrombus formation or bleeding were scaled, 
regardless of the thrombosis model and output parameters, i.e. features that greatly 
differ from laboratory to laboratory.10 
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Using a uniform normalization or scoring approach, we compared in total 1514 
individual studies, investigating deficiencies in 431 mouse genes. Statistical analysis to 
compare 3-point and 5-point scores for different modes of thrombus induction, vascular 
beds and outcome parameters underlined the overall usefulness of a universal 
normalization procedure. It however also revealed subtle differences between 
established collagen-dependent models (i.e., FeCl3 or ligation/compression injury) and 
thrombosis models that were less collagen-dependent (laser or photochemical injury). 
This is in agreement with papers, indicating that the laser model is more dependent on 
tissue factor activity and/or mild endothelial damage, rather than collagen exposure, 
although this may depend on the severity of vascular trauma.29-31 Regression analysis 
pointed to lower significance when comparing high vs. low collagen-dependent models. 
Based on the statistical analysis of the collated data, it can be recommended for 
future thrombosis studies in mice to combine the results of the most commonly 
employed models (FeCl3, ligation and laser injury of the carotid artery) in combination 
with multiple outcome measurements (i.e. not only time-to-occlusion). Taken together, 
the overall agreement in scoring scales – across main experimental variables - indicates 
that, in general, the effect of gene modification is larger than the variation caused by 
differences in methodology or measurement. In a next step, we accumulated the study 
scores per gene (treated as interval variables to allow statistical comparison) to 
calculate the consistency parameter CP as a measure of both the similarity and the 
number of evaluated studies. 
This approach provided a valuable list of 60 consistently studied mouse genes 
(n≥3, CP>2.30), which in majority encode coagulation, platelet membrane or signaling 
proteins contributing to thrombosis and/or hemostasis (Table 2). Together with mouse 
For personal use only.on October 14, 2018. by guest  www.bloodjournal.orgFrom 
19 
 
models of human disease (e.g., Ano6, F8, Itgb3, Nbeal2, Vwf), this list also contains 
many unexpected genes, where the relation to human disease still needs to be 
explored. For these 60 mouse genes/proteins, an overall high homology was present 
with the human orthologues (Suppl. Table 7). Given that only few drug targets are 
currently used for thrombosis treatment, this synthesis approach reveals several 
candidate proteins with a possible role in arterial thrombosis without bleeding. These 
include proteins that modulate functions of platelets, lipids, coagulation or fibrinolysis, as 
well as the vasculature. 
In addition, our list contains only a few thrombosis-suppressive genes (e.g., 
encoding for anticoagulant, fibrinolytic or vascular proteins). For several of these, in 
humans, deficiency is linked to an increased risk of (arterial) thrombosis (protein C, S, 
antithrombin). It will be important now to also investigate the thrombosis risk in humans 
for the other mouse genes with positive thrombosis scaling. On the other hand human 
genetics can also be less straightforward, as exemplified by the observation that a 
mutation of the F5 (factor V) gene linked to altered binding of anticoagulant factors 
leads to a bleeding disorder,32 while the factor V Leiden allele of F5 increases the risk of 
thrombosis. 
For a larger set of 275 modifying mouse genes, information (n≥1, CP ≥1) was 
present regarding a positive or negative role in arterial thrombosis (Data File 3). This 
synthesis approach thus may serve as an alternative for meta-analyses on mouse 
studies outside the field of thrombosis and hemostasis. Our synthesis approach also 
indicates that, for genes implicated in platelet function, measurement of thrombus 
formation using flow chambers in vitro can serve as a proxy test for assessment of 
(collagen-dependent) thrombus formation in vivo. Also, this supports implementation of 
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the 3Rs by: (i) refining in vitro procedures limiting the need for in vivo experiments; (ii) 
reducing numbers of animals, given the relatively small blood volumes needed for in 
vitro tests, and (iii) ultimately replacement of animal by human blood. 
The PITH network revealed a wealth of candidate proteins and pathways 
possibly regulating arterial thrombus formation. Guided by node and centrality 
characteristics of the network, we could identify 4 novel mouse genes with a role in 
thrombus formation. Linking the network to large human databases of genetics of 
hemostasis and arterial thrombosis (Data File 6), mouse-human homology (Data File 4) 
and on-line Mendelian inheritance in man (OMIM) information (Suppl. Table 6) confirms 
its translational relevance. Hence, the PITH network can be used for setting priors when 
analyzing whole exome genome sequencing efforts for patients with rare inherited 
bleeding, thrombotic, or platelet disorders of unknown molecular etiology. It must be 
noted though that not all genes included in the PITH network are expressed in 
megakaryocytes and platelets, that functional redundancy can exist between protein 
isoforms, and that such redundancy can be different across species. Hence, single 
gene or protein deficiencies may not necessarily cause a thrombotic or hemorrhagic 
phenotype. 
The present synthesis approach has also limitations. One restriction is the small 
number of mostly heterogeneous, low-powered studies per gene. The present synthesis 
approach aimed to integrate heterogeneous studies. Correlation analysis indicated 
consistency between the scores of groups and classes, indicating that the grouping and 
synthesis approach is justified. Another limitation is that the compiled mouse data 
include a relatively large set of genes that in man are linked to known inherited bleeding 
disorders, whereas genes with a role in the vascular component of thrombotic disorders 
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are underrepresented. A limitation of the collagen-based in vitro measurements of 
thrombus formation is that anti/pro-thrombotic changes due to altered coagulation, 
fibrinolysis or vascular dysfunction are not easily picked up. 
In summary, this paper demonstrates that a novel synthesis approach based on 
scaling of distinct parameters of thrombus formation can integrate the effects of multiple 
small-size mouse studies to identify: (i) key genes and pathways of thrombotic 
processes in humans, and (ii) new molecular targets for antithrombotic therapy. 
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Table 1. Correlations with scores per study in class I (in vivo thrombus formation) or 
class III (in vitro thrombus formation) for different vascular beds and different triggers. 
Indicated are correlations across genes for similar genetically modified mice, used for studies in 
multiple classes, when scored on 3-point or 5-point scales. N refers to number of comparisons 
(genes) made. Comparison for indicated groups (injury modes, in italic) are indicated relative to 
carotid models (groups 1-4), FeCl3 injury models (groups 1, 6, 9) or in vitro studies (group 30). 
 
  
 3-point  5-point 
 
 Groups N Kendall’s τ P-
value Kendall’s τ 
P-
value 
Compared to carotis (1-4)      
Mesentery 6-8 53 0.80 <0.001 0.53 <0.001 
Cremaster 9-11 27 0.89 <0.001 0.66 <0.001 
 
      
Compared to FeCl3 (1,6,9)      
Laser 8,11 38 0.78 <0.001 0.50   0.001 
Photochemical 2,7,10 27 0.67 <0.001 0.55   0.001 
Ligation & compression 3,5 23 0.59   0.003 0.52   0.005 
 
      
Compared to class III (30)      
Carotis 1-4 77 0.57 <0.001 0.49 <0.001 
Mesentery 6-8 65 0.77 <0.001 0.65 <0.001 
Cremaster 9-11 35 0.80 <0.001 0.64 <0.001 
 
      
FeCl3 1,6,9, 99 0.67 <0.001 0.62 <0.001 
Laser 8,11 36 0.86 <0.001 0.56   0.001 
Photochemical 2,7,10 15 0.26   0.325 0.46   0.056 
Ligation & compression 3,5 24 0.87 <0.001 0.70 <0.001 
Collagen/epinephrine 20 14 0.71   0.006 0.25   0.286 
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Table 2. Mouse and orthologous human genes with consistent contribution to arterial 
thrombosis with(out) altered bleeding. Mouse genes are listed with n ≥ 3 scaled studies (5-
point) and CP values of >2.30 (P < 0.05). Phenotype classification was according to reported 
changes regarding plasma, platelet or vascular phenotypes. Bold: mouse deficiency resulting in 
a highly prolonged bleeding (class IV, score -2). Underlined: human orthologues targeted in 
current clinical practice or trials. 
 
 
  
Altered phenotype Mouse deficiency Human orthologue 
Antithrombotic, no prolonged bleeding 
Plasma coagulation F11, F12 F11, F12 
Plasma fibrinolysis Serpine1 SERPINE1 
Platelet membrane Dusp3, Gp6, Itga6, P2rx1, Selp DUSP3, GP6, ITGA6, P2RX1, SELP 
Platelet signaling Csnk2b,Pik3c3, Pik3cg, Pld1, 
Ppia, Prkca, Rhog, S100a9, 
Sgk1 
 
CSNK2B, PIK3C3, PIK3CG, PLD1,  
PPIA, PRKCA, RHOG, S100A9,  
SGK1 
 
Antithrombotic, prolonged bleeding 
Coagulation F2, F8, F9, Klkb1, Vwf F2, F8, F9, KLKB1, VWF, 
Platelets 
  membrane proteins 
 
Ano6, Clec1b, F2rl3, Fcer1g, 
Fermt3, Gna13, Gnaq, Gp1ba, 
GP1bb, Itga2, Itgb3, Mertk, 
Orai1, P2ry1, P2ry12, Pdia3, 
Pdia4, Ptprj, Stim1, Trpm7, 
Tspan32 
 
ANO6, CLEC1B, F2RL3, FCER1G, 
FERMT3, GNA13, GNAQ, GPIBA,  
GPIBB, ITGA2, ITGB3, MERTK,  
ORAI1, P2RY1, P2RY12, PDIA3,  
PDIA4, PTPRJ, STIM1, TRPM7, 
TSPAN32 
  signaling Csk, Map3k5, Mapk8, Mapk14, 
Pdpk1, Pik3cb, Plcg2, Rac1, 
Rasgrp2, Tln1 
CSK, MAP3K5, MAPK8, MAPK14, 
PDPK1, PIK3CB, PLCG2, RAC1, 
RASGRP2, TLN1 
  secretion/activation Nbeal2, Kcnip3, Mmp2 NBEAL2, KCNIP3, MMP2 
Vessel wall Bambi, Bdkrb2, Mfap2 BAMBI, BDKRB2, MFAP2 
 
Not antithrombotic, prolonged bleeding 
Vessel wall Ceacam1/2 CEACAM1 
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Figure Legends 
 
Figure 1. Flowchart for scaling of parameters of arterial thrombosis and 
thromboembolism. Scored were studies of in vivo arterial thrombus formation (class I), 
thromboembolism (class II), and in vitro thrombus formation (class III) for mice with a 
genetic modification (GM) or pharmacological treatment, in comparison to wild type 
(WT) or the control condition. Indicated are scaling rules (scores) for the various output 
parameters on 3- and 5-point scales (values for WT set at 100%). For detailed 
description of groups and scoring procedures, see Suppl. Table 2. 
 
 
Figure 2. Meta-analysis on contribution of Cd36, Clec1b, F12, Fcer1g, GP6 or Vwf 
mouse genes to prolongation of FeCl3-induced arterial thrombosis. Conventional 
meta-analysis assuming a standard random effects model, to compare effects of 
genetic deficiency in Cd36, Clec1b, F12, Fcer1g, Gp6 or Vwf on prolongation time of 
arterial thrombus formation upon FeCl3 injury. Given per gene are: standardized mean 
difference with 95% confidence interval (CI), test for overall effect (Z), and heterogeneity 
index (I2). See for details Data File 2. 
 
 
Figure 3. Score distribution patterns of studies and mouse genes with increased 
or decreased thrombosis tendency or bleeding. Indicated are score distributions per 
class of numbers of mouse genes (A) or numbers of studies (B). Classes I-III refer to 
arterial thrombosis in vivo, systemic thromboembolism, and thrombus formation in vitro, 
respectively; class IV refers to tail bleeding times. In all cases scoring was at 5-point 
scale. Studies using mice with non-comparable genetics (e.g. gain-of-function 
mutations) were not included. C, Numbers of mouse genes with altered scores in 
classes I-III (5-point scale), in combination with prolonged (-2/-1), unchanged (0) or 
shortened (+1/+2) tail bleeding time (class IV). 
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Figure 4. Consistency analysis for the most frequently studied genes on effects 
on arterial thrombosis. A, Summation of scores per study for 35 indicated genes in 
classes I-III with n≥6. Data obtained from 312 studies (65% collagen-dependent models; 
15% laser models, 7% photochemical injury). B, Mean scores per gene with 95% 
confidence intervals (95% CI). C, Calculated consistency parameter (CP) per gene [1-
log (P)]. Note that a CP value >2.30 corresponds to a P<0.05, and to 95% CI values not 
including zero. 
 
 
Figure 5. Network of protein interactions in thrombosis and hemostasis (PITH). 
Network built in Cytoscape for 275 bait proteins, corresponding to mouse genes with 
modifying effect on arterial thrombosis of hemostasis. The final network has 267 core 
genes (bait nodes), 2679 new nodes, connected by 19721 interactions (edges). Of the 
edges, 15419 are derived from Reactome, 4299 from Intact, and 3 from manual 
assignment. Size of nodes is set as 1 per default, or as CP value. A, Network 
visualization with color-coded bait nodes: proteins modifying thrombosis (blue) or 
thrombosis + bleeding (red). Names are listed of 40 mouse genes with highest CP 
values. B, Network visualization with color-coded proteins linked to rare Mendelian 
disorders of human platelet or coagulant function (green, n=54); proteins linked to high 
association genes in GWAS of platelet count and volume (orange, n=21). C, Network 
visualization with additional purple-coded proteins linked to a recent GWAS of stroke 
(n=11) and coronary artery disease (n=40). D, Network visualization emphasizing 50 
novel nodes with largest number of edges (≥25, yellow). Attribute lists are given in Data 
File 6. The full network, containing gene expression levels in human megakaryocytes33 
and other annotation features, is available in Cytoscape format upon request. For 
enlarged panels, see Suppl. Figure 3. 
 
Figure 6. Role of eight novel mouse genes in arterial thrombus formation, based 
on PITH network. Mice with homozygous deficiency in indicated genes were tested for 
arterial thrombus formation (class III). Data represent surface area coverage (SAC) of 
platelet thrombi on collagen. A-B, Testing of 5 genes/proteins selected from the PITH 
network with suspected thrombosis phenotype. Mean ± SE (n=6-17), **P<0.01. C-D, 
Testing of 3 genes/proteins identified from PITH with suspected gain-of-function defect 
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related to atherothrombosis. Mean ± SE (n=6-18), **P<0.01. B, D, Connecting edges in 
PITH network, and relative mRNA expression in human megakaryocytes (log2 scale).  
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